These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8258230)

  • 1. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
    Wållberg-Jonsson S; Dahlén GH; Nilsson TK; Rånby M; Rantapää-Dahlqvist S
    Clin Rheumatol; 1993 Sep; 12(3):318-24. PubMed ID: 8258230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.
    Öhman M; Öhman ML; Wållberg-Jonsson S
    Scand J Rheumatol; 2014; 43(4):259-64. PubMed ID: 24689997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
    Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
    Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction.
    Bounameaux H; Kruithof EK
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1857-9. PubMed ID: 10938004
    [No Abstract]   [Full Text] [Related]  

  • 6. Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.
    Dimitroulas T; Douglas KM; Panoulas VF; Toms T; Smith JP; Treharne GJ; Nightingale P; Hodson J; Kitas GD
    Clin Rheumatol; 2013 Sep; 32(9):1357-64. PubMed ID: 23673438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
    Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
    Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
    Ozoran K; Dügün N; Gürler A; Tutkak H; Tokgöz G
    Scand J Rheumatol; 1995; 24(6):376-82. PubMed ID: 8610223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
    Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
    J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
    Nilsson TK; Spence JD; Nilsson PM; Eliasson M; Jansson JH; Boman K
    J Cardiovasc Risk; 2002 Aug; 9(4):215-21. PubMed ID: 12394330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
    Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
    Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
    Blann AD; Dobrotova M; Kubisz P; McCollum CN
    Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1.
    Pourtau J; Soria C; Paysant J; Vannier JP; Vasse M
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):609-15. PubMed ID: 9863709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
    Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
    Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
    Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
    Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
    Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.
    Andrianto ; Al-Farabi MJ; Nugraha RA; Marsudi BA; Azmi Y
    Microvasc Res; 2021 Nov; 138():104224. PubMed ID: 34273359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endurance physical activity, diet and fibrinolysis.
    Boman K; Hellsten G; Bruce A; Hallmans G; Nilsson TK
    Atherosclerosis; 1994 Mar; 106(1):65-74. PubMed ID: 8018108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
    Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G
    Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.